NEXGEL appoints Ian Blackman as CFO to lead Celularity acquisition integration
NEXGEL appointed Ian Blackman, CPA, veteran finance executive, as CFO to integrate its license and acquisition agreement for Celularity’s commercial-stage regenerative biomaterials and drive company growth. Blackman brings over 30 years of global financial leadership and previously generated 90% revenue growth and 335% EBITDA increase at McIntosh Group.
1. CFO Appointment and Mandate
NEXGEL named Ian Blackman, CPA, as Chief Financial Officer, tasking him with strengthening the company’s financial infrastructure, treasury operations, tax functions and reporting processes. He will also oversee operational finance and support strategic planning as the company scales its healthcare, beauty and OTC hydrogel business.
2. Integration of Celularity Assets
Blackman will lead the integration of the definitive agreement to license and acquire Celularity’s commercial-stage regenerative biomaterial portfolio, managing due diligence, transaction closing and post-merger operational alignment. This acquisition aims to expand NEXGEL’s regenerative medicine offerings and accelerate growth in its hydrogel technology platform.
3. Executive Track Record
With over 30 years of experience, Blackman drove more than 90% revenue growth and a 335% increase in EBITDA as CFO of McIntosh Group and held senior finance roles at luxury consumer brands. His expertise in high-growth markets and complex transactions is expected to guide NEXGEL’s next phase of expansion and value creation.